However, the Valencia team [44] proposed that the key determinant of immune checkpoint inhibitor efficacy is not gender per se, but rather the 17β-estradiol/ERα/PD-L1 signaling circuit present in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.